The Medical Letter on Drugs and Therapeutics
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
The full article is available to subscribers Subscriber Login   

Tildrakizumab-asmn (Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.1

STANDARD TREATMENT — Topical corticosteroids are generally recommended for initial treatment of mild to moderate plaque psoriasis. The topical retinoid tazarotene (Tazorac, and others) and topical vitamin D analogs such as calcipotriene (Dovonex, and others) can also be used, alone or in combination with topical corticosteroids. For patients with moderate to severe disease, systemic treatment options include biologics, the oral phosphodiesterase type-4 inhibitor apremilast ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
Article code: 1563b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian